EMEA-002027-PIP02-17-M01
Key facts
Active substance |
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0340/2019
|
PIP number |
EMEA-002027-PIP02-17-M01
|
Pharmaceutical form(s) |
Suspension for injection
|
Condition(s) / indication(s) |
Prevention of influenza infection
|
Route(s) of administration |
Intramuscular use
|
Contact for public enquiries |
Adimmune Corporation (Taiwan)
Tel.: +886 425381220 ext.1809 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|